6 recruiting, 2 completed, 2 unknown, 1 active not recruiting. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 6, Completed 2, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 2, Completed 1, Unknown 1 |
Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia Eganelisib, Azacitidine, Venetoclax - Leukemia, Myeloid, Leukemia | Phase 1 | Recruiting | Jacqueline Garcia, MD | 48 | 2026-04-13 | 2026-08-26 |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia Chemotherapy, HLA-mismatched GPBMC infusion, Allogeneic Stem Cell Transplantation - Relapsed Leukemia, Refractory Leukemia | Phase 1 | Recruiting | Beijing 302 Hospital | 5 | 2025-12-01 | 2025-12-22 |
| Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) Roginolisib, Venetoclax, Rituximab - Leukemia, Relapsed Leukemia | Phase 1 / Phase 2 | Recruiting | Jennifer R. Brown, MD, PhD | 64 | 2025-03-19 | 2026-02-11 |
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias STING-Dependent Activators (STAVs) Loaded Autologous Leukemic Cells, Dendritic Cell Vaccine - Refractory Leukemia, Relapsed Leukemia | Phase 1 | Withdrawn | Juan C. Ramos, MD | 2023-11-30 | 2023-12-04 | |
| Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL Olverembatinib, APG-2575, Dexamethasone - Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 19 | 2022-09-01 | 2026-08-26 |
| Tegavivint for the Treatment of Relapsed or Refractory Leukemia Decitabine, Tegavivint - Recurrent Leukemia, Refractory Leukemia | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 9 | 2021-09-27 | 2026-08-25 |
| CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia CAR T-cell therapy - Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia | Phase 1 | Recruiting | National University Hospital, Singapore | 20 | 2021-09-08 | 2021-09-14 |
| Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies Modified anti-CD19 CAR T cells - Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Leukemia | Phase 1 | Unknown | Liqun Zou | 18 | 2021-03-17 | 2022-09-26 |
| Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Allogeneic CD19 CAR-T cells - Relapse Leukemia, Refractory Leukemia | Phase 1 / Phase 2 | Unknown | Shenzhen University General Hospital | 20 | 2021-02-05 | 2021-12-20 |
| Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children Carfilzomib, Cyclophosphamide, Etoposide - Relapsed Solid Tumors, Refractory Solid Tumors | Phase 1 | Completed | Stanford University | 4 | 2016-02-16 | 2025-10-15 |
Leukemia (12) · Leukemia, Myeloid, Acute (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Recurrence (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid (1) · Lymphoma, B-Cell (1)
Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Leukemia, Lymphoid (5) · Leukemia, Myeloid (3) · Disease Attributes (2) · Lymphoma (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Chronic Disease (1)
venetoclax (2) · Azacitidine (1) · Cyclophosphamide (1) · Decitabine (1) · Dexamethasone (1) · Drug Therapy (1) · Etoposide (1) · IPI-549 (1) · Immunotherapy, Adoptive (1) · Injections (1) · Lisaftoclax (1) · Rituximab (1) · carfilzomib (1) · lentiviral minigene vaccine of COVID-19 coronavirus (1) · olverembatinib (1)
Beijing 302 Hospital (1) · Chongqing Precision Biotech Co., Ltd (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jacqueline Garcia, MD (1) · Jennifer R. Brown, MD, PhD (1) · Juan C. Ramos, MD (1) · Liqun Zou (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · National University Hospital, Singapore (1) · Shenzhen University General Hospital (1) · Stanford University (1)
China (5) · United States (5) · Canada (1) · Singapore (1)
Allen Yeoh, M.D (1) · Bo Cai, MD (1) · Dario Campana, M.D, PhD (1) · Jacqueline Garcia, MD (1) · Jennifer Brown, MD, PhD (1) · Jia Wei, M.D (1) · Juan C Ramos, MD (1) · Kuo-Kai Chin, MD (1) · Li Yu, Dr (1) · Tapan M Kadia (1) · Xiaofan Zhu, MD (1)